Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LCB33
- Development stage
- Unknown
- Lead developer
- LigaChem Biosciences, Inc.
- Modality
- Small Molecules
01
Overview
LCB33: sourced facts only. name: "LCB33 ENPP1 inhibitor shows excellent ENPP1 inhibitory activity at an IC50 of 0.9pM and 1nM in enzyme assay using pNP-TMP and cGAMP as substrates, respectively." [DOI:10.1158/1538-7445.am2023-702]; target: "LCB33 ENPP1 inhibitor shows excellent ENPP1 inhibitory activity at an IC50 of 0.9pM and 1nM in enzyme assay using pNP-TMP and cGAMP as substrates, respectively." [DOI:10.1158/1538-7445.am2023-702]; developer: "1LegoChem Biosciences, Inc, Daejeon, Republic of Korea." [DOI:10.1158/1538-7445.am2023-702]; modality: "Taken together, we report a novel and potent small molecule ENPP1 inhibitor in this study." [DOI:10.1158/1538-7445.am2023-702]
02
Targets
ENPP1
Beyond the preview
Go deeper on LCB33.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LCB33.